Galderma will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra®, Relfydess® (RelabotulinumtoxinA) and the Restylane® range.
Galderma’s Global Sensitive Skincare Faculty (GSSF) carried out a clinical study that enrolled 150 women from China aged 35–50 to discover the causes and triggers of sensitive skin. These women represented three distinct profiles: those with a modern lifestyle and sensitive skin; those with a modern lifestyle and non-sensitive skin; and those with a traditional lifestyle and sensitive skin. Data from the study demonstrated a link between modern living—including stress, pollution and lack of sleep—and sensitive skin.
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.
For the full year 2025, Galderma delivered record net sales of 5,207 million USD, exceeding 5 billion USD for the first year. Year-on-year net sales growth for the year was 17.7% at constant currency. Growth overall was predominantly volume-driven, with a favorable product mix more than offsetting pricing effects from the competitive environment.
Galderma has announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.
S&P Global Ratings (S&P) has assigned Galderma a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation.
Galderma announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake. Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership in dermatology and L’Oréal’s expertise as the world’s leading beauty player.
Galderma announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane® syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands. These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and our commitment to continuing to drive innovation in the field.
We are pleased to announce the opening of Galderma’s new Global Capability Center (GCC) in Kraków, Poland. This strategic addition to our global footprint brings a deeper IT-led specialization, further strengthening our technology capabilities, including AI, and supporting our continued growth. Our teams are expected to move into the Kraków GCC by Q3 2026, and we plan to gradually expand our presence in the region over the coming years.
